细胞毒性T淋巴细胞治疗异基因造血干细胞移植后病毒感染的研究进展

Current advance in the treatment of viral infections by cytotoxic T-lymphocytes after allogeneic hematopoiefic stem cell transplantation

病毒感染是异基因造血干细胞移植（allo-HSCT）后常见的并发症,是影响患者长期生存的重要因素.由于细胞毒性T淋巴细胞（CTL）能识别病毒表面抗原,且具有HLA限制性,近来T细胞免疫治疗被用于防治移植后巨细胞病毒（CMV）、EB病毒（EBV）、腺病毒（AdV）等感染.文章就CTL治疗allo-HSCT后病毒感染的研究进展作一总结.

Viral infections remain the common cause of morbidity and mortality in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation （allo-HSCT）.Virus antigens can be recognized by cytotoxic T-lymphocytes （CTL） in the context of HLA class Ⅰ molecules.T-cell-based immunotherapies are now being included in the clinical practice of transplant recipients to prevent and treat viral infections and complications associated with CMV,AdV and EBV.Here,the current status and future feasibility of CTL immunotherapy for virus infections after allo-HSCT are discussed.